Mottola Frank's most recent trade in Supernus Pharmaceuticals Inc was a trade of 14,000 Common Stock done at an average price of $44.5 . Disclosure was reported to the exchange on Aug. 25, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Sale of securities on an exchange or to another person at price $ 44.51 per share. | 25 Aug 2025 | 14,000 | 15,496 (0%) | 0% | 44.5 | 623,140 | Common Stock |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.98 per share. | 25 Aug 2025 | 14,000 | 29,496 (0%) | 0% | 13.0 | 181,720 | Common Stock |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Aug 2025 | 14,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 2,625 | 0 | - | - | Performance Share Units | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Mar 2025 | 2,625 | 16,507 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.11 per share. | 07 Mar 2025 | 1,356 | 15,151 (0%) | 0% | 39.1 | 53,033 | Common Stock |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.05 per share. | 05 Mar 2025 | 945 | 13,882 (0%) | 0% | 33.0 | 31,232 | Common Stock |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.05 per share. | 05 Mar 2025 | 610 | 14,827 (0%) | 0% | 33.1 | 20,161 | Common Stock |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.05 per share. | 05 Mar 2025 | 337 | 15,437 (0%) | 0% | 33.1 | 11,138 | Common Stock |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 3,750 | 0 | - | - | Performance Share Units | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 3,750 | 17,683 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 2,010 | 0 | - | - | Performance Share Units | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2025 | 2,010 | 14,909 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.48 per share. | 26 Feb 2025 | 1,909 | 15,774 (0%) | 0% | 39.5 | 75,367 | Common Stock |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.48 per share. | 26 Feb 2025 | 976 | 13,933 (0%) | 0% | 39.5 | 38,532 | Common Stock |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Feb 2025 | 1,875 | 3,750 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 1,875 | 12,899 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Feb 2025 | 1,250 | 3,750 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 1,250 | 11,024 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 1,125 | 0 | - | - | Performance Share Units | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Feb 2025 | 1,125 | 9,576 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 Feb 2025 | 750 | 750 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 750 | 9,774 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.15 per share. | 21 Feb 2025 | 552 | 9,024 (0%) | 0% | 39.2 | 21,611 | Common Stock |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 20,000 | 20,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 4,500 | 4,500 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2025 | 2,625 | 2,625 | - | - | Performance Share Units | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 3,750 | 3,750 | - | - | Performance Share Units | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 2,010 | 2,010 | - | - | Performance Share Units | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 1,125 | 1,125 | - | - | Performance Share Units | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.13 per share. | 07 Nov 2024 | 15,000 | 23,200 (0%) | 0% | 9.1 | 136,950 | Common Stock |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2024 | 15,000 | 0 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Sale of securities on an exchange or to another person at price $ 36.98 per share. | 07 Nov 2024 | 15,000 | 8,200 (0%) | 0% | 37.0 | 554,700 | Common Stock |
| Supernus Pharmaceuticals Inc | Mottola Frank | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 990 | 8,239 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Mottola Frank | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 990 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.94 per share. | 28 Feb 2024 | 460 | 7,779 (0%) | 0% | 27.9 | 12,852 | Common Stock |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 1,875 | 8,186 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Sale or transfer of securities back to the company at price $ 0.00 per share. | 23 Feb 2024 | 1,875 | 5,625 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Mottola Frank | SVP, Quality, GMP, Ops, IT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 29.06 per share. | 23 Feb 2024 | 937 | 7,249 (0%) | 0% | 29.1 | 27,229 | Common Stock |
| Supernus Pharmaceuticals Inc | Mottola Frank | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 25,000 | 25,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 5,000 | 5,000 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Mottola Frank | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 990 | 990 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Mottola Frank | SVP, Quality, GMP, Ops, IT | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Feb 2024 | 750 | 1,500 | - | - | Restricted Stock Unit | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 750 | 6,646 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.94 per share. | 22 Feb 2024 | 335 | 6,311 (0%) | 0% | 27.9 | 9,360 | Common Stock |
| Supernus Pharmaceuticals Inc | Frank Mottola | Sr VP, Quality, GMP Oper. & IT | Sale of securities on an exchange or to another person at price $ 35.99 per share. | 14 Mar 2023 | 4,780 | 4,737 (0%) | 0% | 36.0 | 172,023 | Common Stock |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 30,000 | 30,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 7,500 | 7,500 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Frank Mottola | Sr VP, Quality, GMP Oper. & IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 750 | 9,517 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Frank Mottola | Sr VP, Quality, GMP Oper. & IT | Sale or transfer of securities back to the company at price $ 0.00 per share. | 22 Feb 2023 | 750 | 2,250 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Frank Mottola | Sr VP, Quality, GMP Oper. & IT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.57 per share. | 22 Feb 2023 | 289 | 9,228 (0%) | 0% | 38.6 | 11,147 | Common Stock |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 1,500 | 8,944 (0%) | 0% | 0 | Common Stock | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 1,500 | 0 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.74 per share. | 16 Feb 2023 | 753 | 8,191 (0%) | 0% | 38.7 | 29,171 | Common Stock |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 1,500 | 1,500 | - | - | Performance Share Unit | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 18,000 | 18,000 | - | - | Employee Stock Option (Right to Buy) | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP, Ops, IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 3,000 | 3,000 | - | - | Restricted Stock Units | |
| Supernus Pharmaceuticals Inc | Frank Mottola | SVP, Quality, GMP Ops. & IT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2021 | 17,000 | 17,000 | - | - | Employee Stock Option (Right to Buy) |